1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Immatics Biotechnologies GmbH - Product Pipeline Review - 2016

Immatics Biotechnologies GmbH - Product Pipeline Review - 2016

  • February 2016
  • -
  • Global Markets Direct
  • -
  • 46 pages

Immatics Biotechnologies GmbH - Product Pipeline Review - 2016

Summary

Global Markets Direct’s, ‘immatics biotechnologies GmbH - Product Pipeline Review - 2016’, provides an overview of the immatics biotechnologies GmbH’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by immatics biotechnologies GmbH, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of immatics biotechnologies GmbH
- The report provides overview of immatics biotechnologies GmbH including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses immatics biotechnologies GmbH’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features immatics biotechnologies GmbH’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate immatics biotechnologies GmbH’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for immatics biotechnologies GmbH
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding immatics biotechnologies GmbH’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table Of Contents

Immatics Biotechnologies GmbH - Product Pipeline Review - 2016
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Immatics Biotechnologies GmbH Snapshot 6
Immatics Biotechnologies GmbH Overview 6
Key Information 6
Key Facts 6
Immatics Biotechnologies GmbH - Research and Development Overview 7
Key Therapeutic Areas 7
Immatics Biotechnologies GmbH - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Partnered Products 11
Partnered Products/Combination Treatment Modalities 12
Pipeline Products - Out-Licensed Products 13
Out-Licensed Products/Combination Treatment Modalities 14
Immatics Biotechnologies GmbH - Pipeline Products Glance 15
Immatics Biotechnologies GmbH - Late Stage Pipeline Products 15
Phase III Products/Combination Treatment Modalities 15
Immatics Biotechnologies GmbH - Clinical Stage Pipeline Products 16
Phase II Products/Combination Treatment Modalities 16
Phase I Products/Combination Treatment Modalities 17
Immatics Biotechnologies GmbH - Early Stage Pipeline Products 18
Preclinical Products/Combination Treatment Modalities 18
Discovery Products/Combination Treatment Modalities 19
Immatics Biotechnologies GmbH - Drug Profiles 20
IMA-901 20
Product Description 20
Mechanism of Action 20
RandD Progress 20
IMA-910 22
Product Description 22
Mechanism of Action 22
RandD Progress 22
APVAC-1 24
Product Description 24
Mechanism of Action 24
RandD Progress 24
APVAC-2 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
IMA-950 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
IMA-101 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
IMA-102 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
IMA-201 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
IMA-202 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
IMA-203 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
IMA-300 35
Product Description 35
Mechanism of Action 35
RandD Progress 35
IMA-301 36
Product Description 36
Mechanism of Action 36
RandD Progress 36
Recombinant Protein for Solid Tumors 37
Product Description 37
Mechanism of Action 37
RandD Progress 37
Immatics Biotechnologies GmbH - Pipeline Analysis 38
Immatics Biotechnologies GmbH - Pipeline Products by Target 38
Immatics Biotechnologies GmbH - Pipeline Products by Route of Administration 39
Immatics Biotechnologies GmbH - Pipeline Products by Molecule Type 40
Immatics Biotechnologies GmbH - Recent Pipeline Updates 41
Immatics Biotechnologies GmbH - Locations And Subsidiaries 44
Head Office 44
Other Locations and Subsidiaries 44
Appendix 45
Methodology 45
Coverage 45
Secondary Research 45
Primary Research 45
Expert Panel Validation 45
Contact Us 45
Disclaimer 46

List of Tables
Immatics Biotechnologies GmbH, Key Information 6
Immatics Biotechnologies GmbH, Key Facts 6
Immatics Biotechnologies GmbH - Pipeline by Indication, 2016 8
Immatics Biotechnologies GmbH - Pipeline by Stage of Development, 2016 9
Immatics Biotechnologies GmbH - Monotherapy Products in Pipeline, 2016 10
Immatics Biotechnologies GmbH - Partnered Products in Pipeline, 2016 11
Immatics Biotechnologies GmbH - Partnered Products/ Combination Treatment Modalities, 2016 12
Immatics Biotechnologies GmbH - Out-Licensed Products in Pipeline, 2016 13
Immatics Biotechnologies GmbH - Out-Licensed Products/ Combination Treatment Modalities, 2016 14
Immatics Biotechnologies GmbH - Phase III, 2016 15
Immatics Biotechnologies GmbH - Phase II, 2016 16
Immatics Biotechnologies GmbH - Phase I, 2016 17
Immatics Biotechnologies GmbH - Preclinical, 2016 18
Immatics Biotechnologies GmbH - Discovery, 2016 19
Immatics Biotechnologies GmbH - Pipeline by Target, 2016 38
Immatics Biotechnologies GmbH - Pipeline by Route of Administration, 2016 39
Immatics Biotechnologies GmbH - Pipeline by Molecule Type, 2016 40
Immatics Biotechnologies GmbH - Recent Pipeline Updates, 2016 41
Immatics Biotechnologies GmbH, Subsidiaries 44

List of Figures
Immatics Biotechnologies GmbH - Pipeline by Indication, 2016 8
Immatics Biotechnologies GmbH - Pipeline by Stage of Development, 2016 9
Immatics Biotechnologies GmbH - Monotherapy Products in Pipeline, 2016 10
Immatics Biotechnologies GmbH - Pipeline by Route of Administration, 2016 39
Immatics Biotechnologies GmbH - Pipeline by Molecule Type, 2016 40

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Tyrosine Protein Kinase Me ...

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016’, provides in depth analysis ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.